Clinical Effect of LG Medipain for Managing Chronic Pain Disorders

Sponsor
Jeeyoun Moon (Other)
Overall Status
Recruiting
CT.gov ID
NCT05165901
Collaborator
(none)
90
1
3
12.4
7.3

Study Details

Study Description

Brief Summary

Scrambler Therapy is a type of non-invasive neuromodulation. According to the researches that studied the effects of the existing Scrambler therapy, 10 times of Scrambler Therapy showed a significant pain relief lasting for more than 1-3 months in various pain disorders such as post-herpetic neuralgia, cancer-related neuropathic pain, and mixed pain. No treatment-related side effects have been reported in Scrambler therapy conducted in previous studies.

The most inconvenient thing about Scrambler Therapy is that it has to be treated more than 10 times during specific period, so frequent visits to the hospital for treatment linked to the higher burden for the patient's cost and even those are not fully covered by the government's insurance. To reduce this discomfort and expand the range of treatment in the era of Corona of untact treatment, LG Electronics devised a home self-scrambler treatment device for pain patients.

The LG Medipain device has the same treatment function as the existing hospital Scrambler treatment device, but there has been no study on its efficacy and safety. Therefore, the investigators want to conduct this research and find out about the safety and equal efficiency of the LG Medipain Therapy.

In this study, it is expected that pain relief and improvement of quality of life can be obtained for patients with various types of chronic pain through self-application of LG Medipain device.

Condition or Disease Intervention/Treatment Phase
  • Device: Scrambler Therapy
N/A

Detailed Description

Scrambler Therapy is a type of non-invasive neuromodulation. Scrambler Therapy is a different type of pain treatment from the theory that converts pain signals into general sensory information (non-pain signals) generated in the human body through artificial neurons and transmits them to the CNS through A-delta and C-nerve fibers, which are pain-transmitting nerve fibers. The non-pain signal converted through Scrambler Therapy exhibits a pain modulatory effect through CNS education, and eventually, the pain signal is continuously disturbed into a pain-free signal, resulting in pain relief. This will function to normalize neuronal plasticity, the cause of chronic pain, which is different from existing pain treatments based on the gate control theory that temporarily blocks or alleviates the recognition of pain stimuli in the CNS.

Scrambler therapy is similar to the existing TENS treatment, but the treatment process is very different from TENS. TENS is a principle that replaces the delivery of pain stimulus to the brain with a stimulus other than pain stimulus and transmits it to the brain. However, Scrambler Therapy is a treatment that reduces the perception of pain in the brain by scrambling the conversion of pain stimulation into electrical signals in the peripheral nerves, similar to TENS, but can convert pain signals into pain-free signals through repetitive brain learning. So to speak, the investigators could state that it is a treatment method that fundamentally suppresses the generation of pain signals.

According to the researches that studied the effects of the existing Scrambler therapy, 10 times of Scrambler Therapy showed a significant pain relief lasting for more than 1-3 months in various pain disorders such as post-herpetic neuralgia, cancer-related neuropathic pain, and mixed pain. No treatment-related side effects have been reported in Scrambler therapy conducted in previous studies.

The most inconvenient thing about Scrambler Therapy is that it has to be treated more than 10 times during specific period, so frequent visits to the hospital for treatment linked to the higher burden for the patient's cost and even those are not fully covered by the government's insurance. To reduce this discomfort and expand the range of treatment in the era of Corona of untact treatment, LG Electronics devised a home self-scrambler treatment device, LG Medipain for pain patients.

While the hospital Scrambler Therapy device uses up to 5 channels (with 10 patches attached) for treatment and the size of the machine is large, the LG Medipain device uses 2 channels (up to 4 patches attached) and is portable and easy to use which is designed to be convenient. The LG Medipain device has the same treatment function as the existing hospital Scrambler treatment device, but there has been no study on its efficacy and safety. Therefore, the investigators want to conduct this research and find out about the safety and equal efficiency of the LG Medipain Therapy. In addition, in order to explore the mechanism of LG Medipain treatment, 30 patients who responded to treatment will be selected and the investigators have plan to examine their EEG waveform of 32 channel with their consents.

After 2 weeks of applying the LG Medipain Therapy for various chronic pain diseases, meaningful (MCD 30% for each group) pain relief effect will be obtained. The purpose of this study is to check whether pain relief can be obtained after 2 weeks of applying 10 times of the LG Medipain therapy for various chronic pain diseases. The secondary purpose of this study is to compare the pain and related-function improvement effects of the LG Medipain Therapy by pain classification. Scrambler treatment has been reported to have a pain relief effect on postherpetic neuralgia, various cancer pains, and musculoskeletal pain through basic 10 applications. In this study, it is expected that pain relief and improvement of quality of life can be obtained for patients with various types of chronic pain through self-application of the LG Medipain device.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
3 different chronic pain classification3 different chronic pain classification
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Effect of LG Medipain for Managing Chronic Pain Disorders: A Prospective Observational Study
Actual Study Start Date :
Jan 3, 2022
Anticipated Primary Completion Date :
Jan 15, 2023
Anticipated Study Completion Date :
Jan 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nociceptive pain

patients with joint pain (knee and shoulder), myofascial pain syndrome

Device: Scrambler Therapy
LG Medipain is a type of non-invasive neuromodulation.

Experimental: Neuropathic pain

patients with postherpetic neuralgia, peripheral nerve injury (CRPS type II, brachial plexopathy, nerve entrapment syndrome)

Device: Scrambler Therapy
LG Medipain is a type of non-invasive neuromodulation.

Experimental: Mixed pain

patients with spine or SIJ origin back and buttock pain or neck pain and SPINE-origin back pain과 neck pain, SIJ-origin back and buttock pain

Device: Scrambler Therapy
LG Medipain is a type of non-invasive neuromodulation.

Outcome Measures

Primary Outcome Measures

  1. Pain relief scoreobtained after 2 weeks of applying [after 2 weeks of applying]

    Pain relief by NRS(Numeric rating scale): from 0(no pain) to 10(worst pain possible)

Secondary Outcome Measures

  1. The painDETECT questionnaire (PD-Q) [during 1 year of treatment]

    The painDETECT questionnaire (PD-Q) for neuropathic pain score assessment

  2. EuroQol-5 dimention(EQ-5D) [during 1 year of treatment]

    EuroQol-5 dimention(EQ-5D) for describing and valuing the health of life

  3. patient global impression of change (PGIC) [during 1 year of treatment]

    patient global impression of change (PGIC) in self-report 5 scale reflects a patient's belief about the efficacy of treatment

  4. Insomnia Severity Index [during 1 year of treatment]

    Insomnia Severity Index for assessing sleep difficulty

  5. Oswestry Disability Index(ODI) [during 1 year of treatment]

    Oswestry Disability Index(ODI) for back & neck functional disability

  6. The Western Ontario and McMaster Universities(WOMAC) Index [during 1 year of treatment]

    The Western Ontario and McMaster Universities(WOMAC) Index to evaluate the patient's Hip and Knee Osteoarthritis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Chronic pain disease (pain over 3 months) as an adult 19 years of age or older

  • Patients with 11-pointed NRS pain score ≥ 4 for the corresponding pain on the day of admission

  • Patients taking oral pain treatment drugs in the same type and dose up to 1 month before participating in the study, and taking the same medication until 1 month after participating in the study (at the time of obtaining the primary endpoint)

  • Those who voluntarily and in writing consent to participate in the study

  • A person who has agreed in writing to return the Scrambler Therapy device

  • By the classification of pain disorder, patients include with nociceptive pain such as joint pain, myofascial pain syndrome and with neuropathic pain such as postherpetic neuralgia, peripheral nerve injury and nerve entrapment syndrome and with mixed pain.

Exclusion Criteria:
  • Refusal of the patient

  • In case pain relief effect was not obtained in the past Scrambler Therapy

  • Patients currently undergoing Scrambler therapy for pain control at outpatient clinics at the Pain Center

  • Patients who had previously taken Scrambler Therapy 6 months before participating in the study

  • In case of systemic infection or local infection in the area around the treatment (the patch attachment site)

  • Patients who has cognitive decline that cannot understand the contents of the Numeric Pain Rating (NRS), questionnaire, and scrambler self application method

  • If it is difficult to self-administer 10 scrambler treatments for 2 weeks during the treatment period

  • Women during pregnancy

  • In case of implantation of a pacemaker, brain stimulator, etc.

  • Those who are not suitable for this clinical trial under the judgment of other investigators

Contacts and Locations

Locations

Site City State Country Postal Code
1 Seoul National University Hospital Seoul Korea, Republic of 110-744

Sponsors and Collaborators

  • Jeeyoun Moon

Investigators

  • Study Director: Jee Yoon Moon, Pf, Seoul national universitiy Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jeeyoun Moon, Chief director, pain management center, Seoul National University Hospital, Seoul National University
ClinicalTrials.gov Identifier:
NCT05165901
Other Study ID Numbers:
  • 2110-017-1260
First Posted:
Dec 21, 2021
Last Update Posted:
May 12, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 12, 2022